Walk into any doctor’s office complaining about erectile dysfunction, and chances are you’ll walk out with a prescription for Viagra, Cialis, or Levitra. It’s almost automatic—erectile problems equal a blue pill (also known as a PDE5 inhibitor prescription).
But here’s the problem: 30-35% of men don’t respond to these medications, and many who do respond initially stop taking them within months.
At NRG Clinic, we see this pattern constantly. Men arrive frustrated after trying multiple ED medications without success, only to discover through hormone blood testing that they’ve been treating a symptom rather than the underlying cause.
The real issue? Between 23% and 47% of men presenting with erectile dysfunction actually have testosterone deficiency, yet most never get tested before being prescribed ED medications.
The Uncomfortable Truth About PDE5 Inhibitors
Phosphodiesterase 5 inhibitors are considered first-line treatment for erectile dysfunction, and they work remarkably well—for about 70% of men. But that still leaves nearly one-third of patients who either don’t respond or aren’t satisfied with the results.
Studies show that prescription renewal rates drop to around 30% by 6-12 months, meaning the majority of men who start these medications have stopped taking them within a year. While some of this relates to improper use or unrealistic expectations, a significant portion stems from an undiagnosed underlying problem: hormone deficiency.
How Testosterone Deficiency Sabotages Erectile Medications
Here’s what most doctors don’t tell you: PDE5 inhibitors are less effective in treating testosterone-deficient men. This isn’t just clinical observation—it’s based on well-established biological mechanisms.
Testosterone directly regulates the expression of PDE5 in penile tissue. In animal studies, surgical castration caused significant reduction in both PDE5 gene and protein expression, and testosterone supplementation completely restored both PDE5 expression and responsiveness to PDE5 inhibitors.
Think about what this means: if you don’t have adequate testosterone, your body doesn’t produce enough PDE5 enzyme.
And if there’s not enough PDE5 present, PDE5 inhibitors have nothing to inhibit.
You’re essentially taking a drug to block an enzyme that your low testosterone has already suppressed.
Testosterone regulation of PDE5 expression has been accepted as one of the major mechanisms controlling vasodilator mechanisms in penile tissue. Without adequate testosterone, the entire erectile machinery doesn’t function optimally—no matter how many pills you take.
The Research That Changes Everything
Multiple studies have demonstrated that men who fail initial treatment with PDE5 inhibitors and have low testosterone show substantial improvement when testosterone therapy is added—with success rates ranging from 37.5% to 92%.
The TADTEST study revealed that adding testosterone to PDE5 inhibitor treatment is beneficial in men with low baseline testosterone levels, and the lower the baseline testosterone, the better the effect.
Another landmark study found that testosterone repletion was associated with enhanced sexual function in patients who failed initial treatment with sildenafil or tadalafil. These weren’t marginal improvements—many non-responders became responders simply by addressing their hormone deficiency.
The Prevalence Problem Nobody Talks About
Testosterone deficiency affects approximately 30% of men aged 40-79, with prevalence strongly associated with common medical conditions including obesity, diabetes, and hypertension—the same conditions that increase erectile dysfunction risk.
Among men with erectile dysfunction, the prevalence of testosterone deficiency can be as high as 33.3%. Yet standard medical practice rarely includes hormone testing before prescribing ED medications.
The prevalence of testosterone deficiency in men presenting with ED was 23%, 33%, and 47% for testosterone levels below 300, 346, and 400 ng/dL respectively. This means that depending on which clinical threshold you use, between one-quarter and nearly half of all men seeking treatment for erectile dysfunction have an underlying hormone problem.
Why Doctors Default to PDE5 Inhibitors
The current medical approach isn’t entirely without logic. PDE5 inhibitors are easy to prescribe, work quickly (when they work), and have relatively few serious side effects for most men. Hormone therapy, by contrast, requires ongoing monitoring, takes longer to show effects, and comes with its own considerations.
But one of the recognized causes of PDE5 inhibitor failure is “unrecognised hypogonadism”—testosterone deficiency that was never diagnosed in the first place. When you skip hormone blood lab testing and jump straight to ED medications, you’re essentially guessing at the solution.
The Biological Connection
Testosterone’s role in erectile function extends far beyond just PDE5 regulation. Research has shown that adequate testosterone is necessary for:
- Proper nitric oxide synthesis and penile vascular dynamics
- Maintaining healthy endothelial function in penile blood vessels
- Preventing smooth muscle degeneration and fibrosis in the corpus cavernosum
- Regulating sexual desire at the central nervous system level
- Coordinating the timing of erections with sexual arousal
Testosterone modulates nearly every component involved in erectile function, from pelvic ganglia to smooth muscle and endothelial cells of the corpora cavernosa. It’s not just one piece of the puzzle—it’s the foundation the entire system is built upon.
The Right Approach: Test First, Treat Smart
Could a Simple Blood Test Replace Your ED Pills?
At NRG Clinic, we believe in addressing root causes rather than just managing symptoms. Our approach starts with hormone blood lab testing because:
- It identifies the real problem: If testosterone deficiency is causing or contributing to erectile dysfunction, no amount of PDE5 inhibitors will fully resolve the issue.
- It prevents wasted time and money: Why spend months or years trying different ED medications when the underlying hormone issue could be corrected?
- It addresses multiple symptoms: Men with testosterone deficiency typically experience more than just erectile problems. They often have low energy, reduced muscle mass, mood changes, and decreased motivation. Treating the hormone deficiency can improve all of these areas.
- It may eliminate the need for ED medications entirely: Many young hypogonadal men suffering from ED due to lack of testosterone find that testosterone therapy alone is sufficient to improve erectile function.
What the Data Shows About Combined Treatment
For men who do need both hormone optimization and PDE5 inhibitors, the research is compelling. Studies show that the combination of testosterone therapy plus PDE5 inhibitors significantly improves erectile function scores compared to PDE5 inhibitors alone in men with hypogonadism.
Meta-analyses demonstrate that testosterone combined with PDE5 inhibitors in patients with ED and hypogonadism seems to further improve symptoms, with many studies showing benefits that neither treatment achieves alone.
The NRG Clinic Difference
We take a different approach because the standard protocol is failing too many men. Our hormone lab panel doesn’t just measure testosterone—it evaluates all the key hormones and metabolic markers that impact erectile function:
- Free and Total Testosterone
- Estrogen Levels (elevated estrogen impairs erectile function)
- Sex Hormone Binding Globulin (affects testosterone availability)
- Thyroid Function (impacts metabolism and erectile function)
- Prolactin (elevated levels suppress testosterone and sexual function)
- Complete metabolic and lipid panels (vascular health is erectile health)
- PSA and other safety markers
This approach allows us to identify not just whether you have low testosterone, but why, and how to treat it most effectively. We have information on our lab tests and how they directly relate to your sexual health and erections.
Stop Guessing, Start Testing
If you’re experiencing erectile dysfunction, you deserve more than a quick prescription and a hope that it works.
You deserve to know what’s actually happening in your body.
The research is clear: screening for hypogonadism in all men with ED is necessary to identify those who may benefit from testosterone treatment. Yet this screening rarely happens.
Studies have found that age, uncontrolled diabetes, high cholesterol, and anemia all correlate with significantly decreased testosterone levels in men with ED. These are testable, treatable conditions—but only if you look for them.
The Bottom Line
If you’re struggling with erectile dysfunction, here’s what you need to know:
- Nearly one-third of men don’t respond adequately to PDE5 inhibitors alone
- Between 23-47% of men with ED have underlying testosterone deficiency
- Low testosterone directly impairs the effectiveness of erectile medications
- Many men who “fail” ED medication simply have undiagnosed hormone issues
- Correcting hormone deficiencies can dramatically improve response to treatment—or eliminate the need for ED medications entirely
Don’t accept a prescription as the first and only step. Hormone testing isn’t just good medicine—it’s the foundation for actually solving the problem.
At NRG Clinic, we start with understanding your complete hormonal picture because treating symptoms without addressing root causes isn’t treatment—it’s just guesswork with a prescription pad.
Ready to stop guessing and start addressing the real issue? Schedule your hormone evaluation at NRG Clinic today. Let’s find out what’s really going on and create a treatment plan that actually works for your body.
References
Zhu J, Zhang W, Ou N, et al. Do testosterone supplements enhance response to phosphodiesterase 5 inhibitors in men with erectile dysfunction and hypogonadism: a systematic review and meta-analysis. Transl Androl Urol. 2020;9(2):591-600.
Alhathal N, Elshal AM, Carrier S. Synergetic effect of testosterone and phophodiesterase-5 inhibitors in hypogonadal men with erectile dysfunction: A systematic review. Can Urol Assoc J. 2012;6(4):269-74.
Köhler TS, Kim J, Feia K, et al. Prevalence of androgen deficiency in men with erectile dysfunction. Urology. 2008;71(4):693-7.
Buvat J, Montorsi F, Maggi M, et al. Hypogonadal men nonresponders to the PDE5 inhibitor tadalafil benefit from normalization of testosterone levels with a 1% hydroalcoholic testosterone gel in the treatment of erectile dysfunction (TADTEST study). J Sex Med. 2011;8:284-93.
Traish AM, Park K, Dhir V, et al. Effects of castration and androgen replacement on erectile function in a rabbit model. Endocrinology. 1999;140:1861-8.
Morelli A, Filippi S, Mancina R, et al. Androgens regulate phosphodiesterase type 5 expression and functional activity in corpora cavernosa. Endocrinology. 2004;145:2253-63.
Martínez-Jabaloyas JM. Testosterone deficiency in patients with erectile dysfunction: when should a higher cardiovascular risk be considered? J Sex Med. 2015;12(10):2026-35.
Pyrgidis N, Mykoniatis I, Haidich AB, et al. The Effect of Phosphodiesterase-type 5 Inhibitors on Erectile Function: An Overview of Systematic Reviews. Front Pharmacol. 2021;12:735708.
Treating erectile dysfunction when PDE5 inhibitors fail. BMJ. 2006;332(7541):589-92.
Aversa A, Duca Y, Condorelli RA, et al. Androgen Deficiency and Phosphodiesterase Type 5 Expression Changes in Aging Male: Therapeutic Implications. Front Endocrinol. 2019;10:225.
